Physician profile
Vincent Shen
NPI 1881751261
$1,054.99
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $135 · 2021: $49.35 · 2022: $26.77 · 2023: $123 · 2024: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $311.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $145.66 | 2019 | |
| Amgen INC. | $113.25 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $92.90 | 2019-2024 | |
| Janssen Biotech, INC. | $69.31 | 2019-2024 | Darzalex, Imbruvica, Tecvayli |
| Genzyme Corporation | $59.70 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $46.38 | 2023-2024 | Libtayo |
| Incyte Corporation | $43.21 | 2019-2023 | Jakafi |
| Advanced Accelerator Applications | $37.05 | 2019-2020 | |
| Lilly USA, LLC | $34.75 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $33.83 | 2020-2023 | Breztri |
| Eisai INC. | $31.28 | 2019-2024 | |
| Pfizer INC. | $30.00 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $27.32 | 2019 | |
| Gilead Sciences, INC. | $27.15 | 2019-2021 | |
| Tesaro, INC. | $25.41 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.49 | 2021 | |
| Celgene Corporation | $23.50 | 2023 | Pomalyst |
| Agios Pharmaceuticals, INC. | $20.05 | 2024 | |
| Dova Pharmaceuticals | $19.07 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.73 | 2023 | Ofev |
| Amag Pharmaceuticals, INC. | $17.79 | 2020 | |
| Tempus Ai, INC | $15.90 | 2024 | |
| Tersera Therapeutics LLC | $15.89 | 2024 | Zoladex |
| Genentech USA, INC. | $14.82 | 2019 | |
| Abbvie INC. | $14.51 | 2024 | |
| Daiichi Sankyo INC. | $12.93 | 2019 | |
| Glaxosmithkline, LLC. | $12.59 | 2020 | |
| Array Biopharma INC | $12.46 | 2019 | |
| Kite Pharma, INC. | $11.84 | 2020 | |
| Clovis Oncology, INC. | $3.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.